Serum miR-9 as a prognostic biomarker in patients with osteosarcoma
Dan Fei, Yang Li, Dongxu Zhao, Kaijun Zhao, Lu Dai, Zhongli Gao, Dan Fei, Yang Li, Dongxu Zhao, Kaijun Zhao, Lu Dai, Zhongli Gao
Abstract
Objectives: To quantify microRNA-9 (miR-9) concentrations in the serum of patients with osteosarcoma; to explore its relationship with clinicopathological characteristics and prognosis of osteosarcoma.
Method: Serum miR-9 was quantified via real-time reverse transcription-polymerase chain reaction in patients with osteosarcoma and healthy control subjects. Overall survival was evaluated using the Kaplan-Meier method.
Results: Serum miR-9 was significantly upregulated in patients with osteosarcoma (n = 118) compared with healthy control subjects (n = 60); its upregulation was significantly associated with advanced tumour-node-metastasis stage, larger tumour size and presence of distant metastasis. Overall survival duration was significantly shorter in patients with relatively high miR-9 concentrations compared with those with relatively low miR-9 concentrations.
Conclusions: Serum miR-9 concentrations are significantly increased in patients with osteosarcoma compared with healthy controls. Upregulation of miR-9 is associated with tumour stage, size and metastasis. Serum miR-9 quantification may represent a useful diagnostic and prognostic marker of osteosarcoma.
Keywords: MicroRNA-9; osteosarcoma; serum.
© The Author(s) 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.
Source: PubMed